Ubs Group Ag Sera Prognostics, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Sera Prognostics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 86,784 shares of SERA stock, worth $224,770. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,784

Previous 67,046 29.44%

Holding current value

$224,770

Previous $581,000 45.09%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$3.54 - $8.33 $69,872 - $164,417	19,738 Added 29.44%	86,784 $319,000
Q4 2024 Feb 14, 2025	BUY	$6.03 - $8.83 $149,984 - $219,628	24,873 Added 58.98%	67,046 $581,000
Q3 2024 Nov 14, 2024	BUY	$5.29 - $8.43 $94,273 - $150,231	17,821 Added 73.18%	42,173 $328,000
Q2 2024 Aug 13, 2024	BUY	$5.6 - $11.69 $20,692 - $43,194	3,695 Added 17.89%	24,352 $144,000
Q1 2024 May 13, 2024	BUY	$5.05 - $10.0 $22,295 - $44,150	4,415 Added 27.18%	20,657 $187,000
Q4 2023 Feb 09, 2024	SELL	$1.65 - $6.85 $7,850 - $32,592	-4,758 Reduced 22.66%	16,242 $97,000
Q3 2023 Nov 09, 2023	SELL	$1.55 - $3.34 $3,605 - $7,768	-2,326 Reduced 9.97%	21,000 $39,000
Q2 2023 Aug 11, 2023	SELL	$3.0 - $3.98 $3,558 - $4,720	-1,186 Reduced 4.84%	23,326 $76,000
Q1 2023 May 12, 2023	BUY	$1.19 - $4.25 $29,169 - $104,176	24,512 New	24,512 $93,000
Q3 2022 Nov 10, 2022	BUY	$1.55 - $2.71 $10,992 - $19,219	7,092 Added 261.41%	9,805 $16,000
Q2 2022 Aug 10, 2022	BUY	$1.2 - $3.62 $678 - $2,045	565 Added 26.3%	2,713 $4,000
Q1 2022 May 16, 2022	SELL	$2.96 - $8.8 $2,039 - $6,063	-689 Reduced 24.29%	2,148 $8,000
Q4 2021 Feb 14, 2022	BUY	$6.87 - $11.41 $19,490 - $32,370	2,837 New	2,837 $19,000

Others Institutions Holding SERA

# of Institutions

Shares Held

22.6M

Call Options Held

300

Put Options Held

800

View Full List

About SERA PROGNOSTICS, INC.

Ticker SERA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 29,596,900
Market Cap $76.7M
Description
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product ...

More about SERA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account